Search Results - "Rosello Keranen, S."

RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial by Sclafani, F, Gonzalez, D, Cunningham, D, Hulkki Wilson, S, Peckitt, C, Giralt, J, Glimelius, B, Roselló Keränen, S, Wotherspoon, A, Brown, G, Tait, D, Oates, J, Chau, I

“…Abstract Background RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We…”
Get full text

64P Integrative immune transcriptomic classification could improve patient selection for precision immunotherapy in advanced gastroesophageal adenocarcinoma by Cabeza Segura, M., Gambardella, V., Gimeno-Valiente, F., Carbonell-Asins, J.A., Alarcon-Molero, L., Gonzalez-Vilanova, A., Zuniga-Trejos, S., Rentero-Garrido, P., Villagrasa, R., Gil Raga, M., Richart, P., Huerta, M., Rosello Keranen, S., Roda Perez, D., Tarazona Llavero, N., Martínez-Ciarpaglini, C., Castillo, J., Cervantes, A., Fleitas, T.C.

Get full text

379P Whole exome sequencing of plasma circulating tumor DNA identifies dynamic mutational changes to guide targeted therapies in colon cancer patients by Martín-Arana, J., Gimeno-Valiente, F., Tébar-Martínez, R., García-Mico, B., Gambardella, V., Huerta, M., Martínez-Ciarpaglini, C., Carbonell-Asins, J.A., Cabeza Segura, M., Martín-Arévalo, J., Casado, D., Pla, V., Pérez, L., Rentero-Garrido, P., Rosello Keranen, S., Fleitas, T.C., Castillo, J., Roda Perez, D., Cervantes, A., Tarazona Llavero, N.

Get full text

CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations by Castillo, J., Papaccio, F., Valiente, F.G., Gutierrez-Bravo, M.F., Cabeza-Segura, M., Gambardella, V., Huerta, M.D.S., Martinez-Ciarpaglini, C., Alfaro-Cervello, C., Rentero-Garrido, P., Zúñiga-Trejos, S., Rosello Keranen, S., Fleitas, T., Tarazona, N., Roda Perez, D., Cervantes, A.

Get full text

638P - Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine by Papaccio, F., Gutierrez-Bravo, M.F., Cabeza-Segura, M., Gambardella, V., Huerta, M., Ciarpaglini, C Martinez, Keranen, S Rosello, Gimeno-Valiente, F., Fleitas, T., Llavero, N Tarazona, Roda, D., Cervantes, A., Castillo, J.

“…Organoids are 3D in vitroprimary culture of great interest for translational research representing an efficient and reproducible cancer model. The aim of this…”
Get full text

Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine by Papaccio, F., Gutierrez-Bravo, M.F., Cabeza-Segura, M., Gambardella, V., Huerta, M., Ciarpaglini, C Martinez, Keranen, S Rosello, Gimeno-Valiente, F., Fleitas, T., Llavero, N Tarazona, Roda, D., Cervantes, A., Castillo, J.

Get full text

638PDevelopment of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine by Papaccio, F, Gutierrez-Bravo, M F, Cabeza-Segura, M, Gambardella, V, Huerta, M, Ciarpaglini, C Martinez, Keranen, S Rosello, Gimeno-Valiente, F, Fleitas, T, Llavero, N Tarazona, Roda, D, Cervantes, A, Castillo, J

“…Abstract Background Organoids are 3D in vitroprimary culture of great interest for translational research representing an efficient and reproducible cancer…”
Get full text

28PCNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations by Papaccio, F, Valiente, F G, Gutierrez-Bravo, M F, Cabeza-Segura, M, Gambardella, V, Huerta, M D S, Martinez-Ciarpaglini, C, Alfaro-Cervello, C, Rentero-Garrido, P, Zúñiga-Trejos, S, Rosello Keranen, S, Fleitas, T, Tarazona, N, Roda Perez, D, Cervantes, A, Castillo, J

“…Abstract Background Colorectal cancer (CRC) patients derived organoids (PDOs) are 3D in vitro primary culture representing an increasingly used model for…”
Get full text

Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype by Llavero, N Tarazona, Gimeno-Valiente, F., Gambardella, V., Huerta, M., Keranen, S Rosello, Bruixola, G., Fontana, E., Ciarpaglini, C Martinez, Zuñiga, S., Rentero, P., Fleitas, T., Papaccio, F., Moro, D., Pla, V., Nyamundanda, G., Castillo, J., Sadanadam, A., Espí, A., Roda, D., Cervantes, A.

Get full text

522OMutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype by Llavero, N Tarazona, Gimeno-Valiente, F, Gambardella, V, Huerta, M, Keranen, S Rosello, Bruixola, G, Fontana, E, Ciarpaglini, C Martinez, Zuñiga, S, Rentero, P, Fleitas, T, Papaccio, F, Moro, D, Pla, V, Nyamundanda, G, Castillo, J, Sadanadam, A, Espí, A, Roda, D, Cervantes, A

“…Abstract Background Although staging provides prognostic information and guides therapeutic decisions, 30-50% of patients with localized CRC will relapse…”
Get full text

522O - Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype by Llavero, N Tarazona, Gimeno-Valiente, F., Gambardella, V., Huerta, M., Keranen, S Rosello, Bruixola, G., Fontana, E., Ciarpaglini, C Martinez, Zuñiga, S., Rentero, P., Fleitas, T., Papaccio, F., Moro, D., Pla, V., Nyamundanda, G., Castillo, J., Sadanadam, A., Espí, A., Roda, D., Cervantes, A.

“…Although staging provides prognostic information and guides therapeutic decisions, 30-50% of patients with localized CRC will relapse despite optimal primary…”
Get full text

Evaluation of results after 112 radioembolizations with 90Y-microspheres by Casáns-Tormo, I., Guijarro-Rosaleny, J., Lluch-García, P., Rodríguez-Parra, H., Roselló-Keränen, S., Asensio-Valero, L.

“…To determine the results of radioembolization transarterial (TARE), in the treatment of liver tumors, a retrospective evaluation was performed after 112 TARE…”
Get full text

2052 POSTER Incidence of chemotherapy induced amenorrhea and the role of hormone therapy on ovarian function in hormone sensitive breast cancer by Garcia Garre, E, Rosello-Keranën, S, Jorda, E, Perez-Fidalgo, A, Martin, P, Bermejo, B, Chirivella, I, Magro, A, Insa, A, Lluch, A

Get full text

340P Prediction of relapse in colon cancer patients by machine learning models combining radiomics and deep features extracted from baseline computed tomography by Bueno Gómez, A., Tarazona Llavero, N., Alcolado Jaramillo, A., Gimeno-Valiente, F., Carbonell-Asins, J.A., Huerta, M., Fleitas, T.C., Roselló Keränen, S., Candia, L.M., Roda Perez, D., Moreno Ruiz, P., Jiménez Pastor, A., Alberich-Bayarri, A., Cervantes, A.

Get full text

360P Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer by Gimeno-Valiente, F., Duréndez, E., Badía, J., Martínez-Ciarpaglini, C., Iglesias, M., Linares, J.L., Huerta, M., Moro, D., Gambardella, V., Martín-Arana, J., Fleitas, T.C., Roselló Keränen, S., Cabeza Segura, M., García-Mico, B., Rentero-Garrido, P., Roda, D., Castillo, J., Cervantes, A., Calon, A., Tarazona Llavero, N.

Get full text

Breast cancer metastases in the iris: does treatment modifies natural history of the illness? by Pérez-Fidalgo, J A, Vila Arteaga, J, Chirivella González, I, Martínez Belda, R, Bermejo de Lasheras, B, Roselló Keranën, S, Fons Moreno, A, Lluch Hernández, A

“…The 4-5% of the breast cancer patients have metastases in the eye. We present the case of a 30-year-old woman with an infiltrant duct carcinoma of the breast…”
Get full text

1493P An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models by Gambardella, V., Gimeno-Valiente, F., Cabeza, M., Papaccio, F., Zúñiga-Trejos, S., Carbonell-Asins, J.A., Rentero-Garrido, P., Huerta, M., Roselló Keränen, S., Cejalvo, J.M., Roda, D., Tarazona, N., Fleitas, T., Cervantes, A., Castillo, J.

Get full text

P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens by Tabernero, J., Fernandez, E. Elez, Ghiringhelli, F., Folprecht, G., Curigliano, G., Siena, S., Cremolini, C., Sobrero, A., Kwiatek, M., Keränen, S. Roselló, Ahn, D., Punt, C., Laurent, D., Ferrara, M., Pellacani, A., Capriati, A.

Get full text

Evaluation of results after 112 radioembolizations with 90 Y-microspheres by Casáns-Tormo, I, Guijarro-Rosaleny, J, Lluch-García, P, Rodríguez-Parra, H, Roselló-Keränen, S, Asensio-Valero, L

“…To determine the results of radioembolization transarterial (TARE), in the treatment of liver tumors, a retrospective evaluation was performed after 112 TARE…”
Get full text

1565P Clinical outcome after perioperative treatment on locally advanced and borderline pancreatic cancer: Experience of a single academic center by Roselló Keränen, S., Pizzo, C., Huerta, M., Muñoz, E., Alfaro-Cervello, C., Aliaga, R., Vera, A., Jordá, E., Garcés, M., Roda, D., Tarazona, N., Dorcaratto, D., Guijarro, J., Sánchiz, V., Fleitas, T., Lluch, P., Pascual, I., Ferrandez, A., Cervantes, A., Sabater, L.

Get full text